May/June 2023

The Effect of Biosimilars on Clinical Practice

A look at the true cost of the new drugs that are shaking up our therapeutic approaches.

Margaret M. Runner, MD, and George A. Williams, MD

Tackling Geographic Atrophy With Gene Therapy

Stopping atrophy at the source—our genes—may one day be an effective treatment approach.

Rebecca Hepp, Editor-in-Chief

Macular Degeneration: Time to Focus on Vision

It’s all about seeing better for patients with geographic atrophy and wet AMD. These tools and surgical interventions may help.

Alex Brodin

Angiogenesis 2023: Quick Hits

See what you missed at this year’s virtual gathering.

The End of the Beginning

Allen C. Ho, MD, and Robert L. Avery, MD

Beware of AMN With COVID-19 Infection

A potential ocular complication that can lead to a reduction in visual acuity.

Evgeniia Perevoznikova, MD; Vlatka Brzović Šarić, MD, PhD; and Nenad Vukojević, MD, PhD

No More Forceps: A Cutter-based Approach to ILM Peeling

This technique could reduce surgical time, improve patient satisfaction, and save on instrument costs.

Scott Walter, MD, MSc, and Simon Archambault, MD, MSc

Surgical Technique for Scleral-Fixated IOLs

A challenging but beneficial approach for cases with poor capsular support.

Alejandro Londoño, MD; Daniel Francisco Lopez, MD; Natalia Trujillo Ángel, MD; and Andrés Amaya Espinosa, MD

Geographic Atrophy Treatment Pearls

Experts share their insights on caring for a whole new patient population with newly approved therapeutics.

Eleonora M. Lad, MD, PhD; Jeffrey S. Heier, MD; Dilsher S. Dhoot, MD; Allen C. Ho, MD; and Robert L. Avery, MD

A Look at Novel Geographic Atrophy Biomarkers

Multimodal imaging is now the standard for diagnosing dry AMD—here’s what you need to know.

Farhan E. Hiya, MD; Abrahim Ahmed, BS; and David A. Eichenbaum, MD

The Complement System: A New Therapeutic Target

A deeper understanding of the innate immune system is opening new avenues for the treatment of geographic atrophy.

Aumer Shughoury, MD, and Thomas A. Ciulla, MD, MBA

Clinical Trial Designs in Wet AMD: A Brief Review

Can newer therapies improve upon visual acuity and other outcomes for patients?

Carl D. Regillo, MD

Quantifying Fluid in AMD

Central subfoveal thickness isn’t the only biomarker clinicians can use to track disease progression and treatment effect.

Stela Vujosevic, MD, PhD, FARVO, FEBO

Diagnostic Yield in Non-Dilating Pupils

Scanning laser ophthalmoscopy-based fundus photography can help to diagnose patients with non-dilating pupils.

Manish Nagpal, MS, FRCS, FASRS; Navneet Mehrotra, MBBS, DNB, FRF; Akansha Sharma, MBBS, MS; and Abhishek Verma, MBBS, DO

Spontaneous Hyphema From Small Cell Lung Cancer Metastasis

External beam radiation therapy can be a good option to control ocular manifestations when systemic disease is widespread.

Eric Lien, BS; Ferris Bayasi, MD; and Carol L. Shields, MD

Catching Bietti Crystalline Dystrophy Early

Prominent retinal deposits in the early stage may be helpful for diagnosis.

M. Giray Ersoz, MD, FEBO; Rouzbeh Abbasgholizadeh, MD; and Metin Suleymanzade, MD